Background The benefit of cardiac resynchronization therapy (CRT) among patients with mild heart failure (HF), reduced left ventricular (LV) function and wide QRS is well established. We studied the long-term stability of CRT.
Introduction
Cardiac resynchronization therapy (CRT) is well established for patients with left ventricular (LV) systolic dysfunction and ventricular conduction delay. Initially, CRT was shown to improve the functional status and quality of life (QoL), as well as reduce hospitalization and mortality among patients with advanced heart failure (HF) (NYHA Class III and IV). 1 -3 Accompanying these clinical endpoints was reverse remodelling by decreased left ventricular dimensions and increased left ventricular ejection fraction (LVEF). 4, 5 More recently, similar benefits by CRT were reported in mild HF (NYHA Class I and II). 6 -8 REVERSE was one of three large studies of CRT in mild HF, with the primary endpoints at 12 months 6 and the 2-year 9 followup data published previously that has resulted in guidelines recommendation for CRT in NYHA Class II patients. 10 Despite the consistent benefit of CRT observed in these randomized clinical trials, there are little data on the long-term benefit of this therapy. 8, 11 To address such potential long-term benefit, REVERSE was designed prospectively for 5-year follow-up with annual echocardiographic, clinical, and functional assessment as part of secondary endpoints. The present analysis was performed to assess the magnitude and sustained effect of CRT over a prolonged follow-up period.
Methods REVERSE was a prospective, randomized, double-blind, parallelcontrolled multinational study designed to determine whether CRT limited the progression of HF compared with optimal medical therapy alone. The study included ACC/AHA stage C, NYHA Class I or II HF patients with QRS ≥120 ms, and LVEF ≤40% on optimal medical therapy. Patients were implanted with a CRT-device with (CRT-D) or without (CRT-P) defibrillator and randomized 2:1 to CRT ON or CRT OFF. Patients were then programmed as randomized through 12 months in North America 6 and through 24 months in Europe. 9 By the study design, 12 all patients were programmed to CRT ON after the randomization period and followed for 5 years from implantation. First enrolment occurred in September 2004, and enrolment was completed in September 2006. The final 5-year follow-up was in November 2011. The present analysis is confined to subjects randomized to CRT ON, who received up to 5 years of CRT therapy.
Outcomes
Long-term results analysis pre-specified in the protocol included NYHA class, 6-min hall walk, QoL, echocardiographic parameters, all-cause mortality, adverse events, and HF hospitalization. The primary endpoint in the main study was the clinical composite endpoint 13 and the second powered endpoint was reverse remodelling measured by the left ventricular end-systolic volume index (LVESVi). Quality of life was measured by the Minnesota Living with heart failure Questionnaire and the Kansas City Cardiomyopathy (KCCQ) questionnaire. During the randomized period, patients were evaluated every 6 months with NYHA class, 6-min hall walk, and QoL by medical staff unaware of randomization assignment. Thereafter, patients were evaluated annually by staff unblinded to CRT programming. Likewise, echocardiographic data were assessed by core-labs and HF-related hospitalizations and mortality data by an independent endpoint committee unaware of CRT programming for the randomized phase of the study and thereafter unblinded to programming.
Adverse effects
To assess risk of CRT therapy and balance it to potential benefit, analysis was focused on LV lead-related adverse events requiring invasive intervention or resulting in termination of significant device function as adjudicated by the independent Adverse Event Advisory Committee over the 5 years of study follow-up.
Statistical methods
All the patients randomized to CRT ON with data available were used in all analyses. There was no imputation of missing data. Continuous variables are reported as mean + standard deviation. Survival analysis was performed using the Kaplan-Meier method. Information on hospitalizations was available in 369 of 419 CRT ON patients for the entire 5-year period. The other 50 patients were in a subset (17 of 35) of European centres and the Canadian centre which did not collect hospitalizations after randomized follow-up (12 or 24 months). Patients at these centres were censored from the Kaplan -Meier curve on their last date of randomized follow-up. All hospitalizations collected through randomized follow-up and all hospitalizations through 5 years in the USA were adjudicated for HF relatedness by the AEAC. In Europe after 2 years, the investigator answer to the question 'Was worsening of heart failure signs/symptoms the reason for admission or an event which occurred during the patient's hospitalisation?' was used as adjudication. One-sample t-tests were used to compute P-values, and the P-values were not adjusted for multiplicity.
Results
Of 610 randomized patients, 419 were assigned to have CRT ON and used in this analysis ( Figure 1 ). Over an average follow-up of 54.8 + 13.0 months, 12 (2.9%) patients permanently discontinued CRT, due to diaphragmatic stimulation or worsening HF and 31 patients had CRT temporarily suspended over a median duration of 17 days due to left ventricular lead dislodgement, erroneous programming, or diaphragmatic stimulation. Of patients alive, 95, 89, and 86% completed follow-ups at 3, 4, and 5 years post-randomization, respectively.
Patient characteristics
The baseline characteristics of the 419 CRT ON patients are summarized in Table 1 and are similar to the overall cohort. 6 Patients were very well-treated medically with over 95% receiving betablockers and ACE inhibitors or angiotensin receptor blocker agents.
Echocardiographic measurements
The results of the serial echocardiographic evaluations made by the core-labs throughout the follow-up period are summarized in Table 2 and Figure 2 . The largest reduction in LVESVi, occurred in the first year of CRT with a mean change of 18.4 + 28.9 mL/m 2 , P , 0.0001 with further improvement over the second year of 5.2 + 18.8 mL/ m 2 , P , 0.0001. Thereafter, the benefit was sustained with no evidence of attenuation of response over 5 years of follow-up. Similar changes were noted for left ventricular end-diastolic volume index and LVEF.
Clinical measurements
The baseline values and the changes from baseline to each follow-up visit of the 6-min hall walk, QoL questionnaires, and NYHA class distribution are shown in During the follow-up time of 54.8 + 13.0 months, 53 patients died due to HF in 40% (n ¼ 21), sudden cardiac death in 19% (n ¼ 10), and for non-cardiac causes in 42% (n ¼ 22). Total mortality and time to first HF hospitalization or death are shown in Figure 3A and B. The 5-year mortality was 13.5% (95% CI: 10.4-17.4%) with an average annual mortality of 2.9%. The percentage of patients with first HF-related hospitalization at 5 years was 22.0% (95% CI: 18.0-26.7%) with an annual rate of 4.8%. The incidence of the combined endpoint was 28.1% (95% CI: 23.7-33.1%) and remained linear over the follow-up period with an annual rate of 6.4%.
Adverse effects
Among the 419 patients, 51 (12.2%) experienced 63 LV lead-related complications. Most events occurred within the first 3 months of implant ( Figure 4 ) with a rate of 7.9% (95% CI: 5.7 -10.9%), and a rate of 12.5% (95% CI: 9.6-16.2%) at 5 years. The majority were due to LV lead dislodgment (n ¼ 33) and/or diaphragmatic stimulation (n ¼ 10). Over the course of the 5-year follow-up, 132 of the 419 patients (31.5%) underwent device replacement.
Discussion
The most important finding of this pre-planned 5-year analysis from the REVERSE study was that CRT was associated with low rates of HF hospitalization and all-cause mortality over the entire follow-up. This is the first study to show that CRT not only produced large structural changes in mild HF patients within 2 years, but also had sustained long-term effects. In contrast, measures of symptomatic improvement were less clear with early improvement that decreased over the latter half of the monitoring period.
Reverse remodelling
Reverse remodelling is one of the hallmark findings of CRT studies in both mild and advanced HF subjects with echocardiographic changes believed to be a major mechanism of action. CARE HF is the only other large randomized study with serial echocardiographic assessment beyond 1 year. 5 The unique aspect of the present study was the serial evaluation of echocardiographic findings over a 5-year period. Similar to CARE-HF, we observed that the largest change in LV volumes was noted in the first year with further remodelling over at least one additional year suggesting that the full effect of CRT is achieved within this time range. Further remodelling is unlikely thereafter. Moreover, we have previously reported that significant reverse LV remodelling at a threshold of .15% reduction in LVESVi at 12 months was associated with a clinical response to CRT. 14 Others have found that a decrease in LV volumes of 10% is associated with outcomes benefit. 15 
Overall mortality and morbidity
The large early and sustained reverse left ventricular remodelling effect by CRT was accompanied by a low rate of HF hospitalization and mortality. These rates were lower than those observed in CRT studies of both advanced 2,3 and mild HF. 6 -9 The mean event rate in the CRT arm of the primary endpoint in both MADIT CRT 7 and RAFT 8 trials of mortality and HF hospitalization was somewhat higher than in the present study. It was 17.2% in MADIT CRT at 24 months that represents an annual rate of 9.0%. In the NYHA Class II patients in RAFT, the 40 months event rate was 27.3%, translating into a 9.1% annual event rate. It is also very much better than the 56% event-free survival rate reported in the retrospective follow-up of a CRT-P or CRT-D registry, which mainly included NYHA Class III and IV patients. 16 In the present study with an even longer follow-up, the annual event rate was somewhat lower at 6.4% which was consistent over the follow-up indicating that the benefit of CRT on clinical events is sustained for at least 5 years. The mortality rate in the present study is also somewhat lower than the corresponding rate in the primary preventive ICD studies primarily focusing on improving survival in patients with depressed LV function. In the SCD-HeFT trial, 17 the annual mortality rate in the ICD arm was 7.6% with a mean follow-up time of 45.5 months and in the MADIT II 18 study it was 6.4% over an 8-year follow-up. However, the comparison with the present study is not entirely relevant since not all patients in those studies had HF. Moreover, ICD therapy alone can only reduce sudden deaths and may even increase the risk for HF exacerbation and mortality if the right ventricular pacing percentage is high or if HF develops during treatment. 18 The rates of mortality HF morbidity observed in our study are also lower than in drug studies of patients with mild HF such as the CHARM and EMPHASIS trials. 19, 20 Since the REVERSE patients received CRT on top of optimal medical therapy, our results suggest a strong additive benefit of combining these therapeutic approaches and that such a regime results in long-term benefit.
The duration of effects of HF therapy is seldom reported. In the CONSENSUS trial, the survival benefit of enalapril in severe HF persisted over a 4-year period 21 similar to REVERSE. But unlike CONSENSUS, REVERSE focuses on halting or reverting disease progression in mild HF further delaying the deterioration in left ventricular function and onset of HF.
Symptomatic improvement
Quality of life improved over the study follow-up by both QoL scores. Despite the fact that such measurements are subject to placebo effect, 22 entire study period. In contrast the benefits regarding 6-min hall walk and NYHA functional status were not sustained over time. It is difficult to reconcile these findings in the absence of structural deterioration or changes in HF hospitalizations. This observation may reflect the fact that part of the initial improvement was related to placebo effects and this effect waned over time revealing the Cells have mean + SD, the 95% confidence interval for the mean, and n in parentheses or n (%). A decrease in the Minnesota QoL score indicates benefit. An increase in the Kansas City Cardiomyopathy QoL score indicates a benefit. true treatment effect. An alternative explanation is that increasing age during the 5-year study influenced exercise tolerance hence NYHA class to a greater extent than QoL measures. Whether this represents the inaccuracies of the long-term follow-up and repeated measures on the subjective components of these 'softer' endpoints or a real dissociation between different endpoints warrants further study.
Clinical implications
The present study demonstrates very low mortality rates and low and stable HF events with CRT in mild HF. This supports the costeffectiveness of CRT in the presence of LV systolic dysfunction and mild HF symptoms already reported. 23 With the large majority of study patients requiring an ICD, complications related to the LV lead substantiate the incremental risk of CRT. Left ventricular lead-related adverse events requiring invasive intervention or resulting in termination of significant device function as adjudicated by the independent Adverse Event Advisory Committee were relatively few and lower than what the 16% complication rate (LV 11%, RV 5%) reported in NYHA Class III and IV patients with 6-month follow-up 24 and comparable to the reported European CRT Survey with 1-year follow-up (10.3%). 25 Moreover, no study of comparable follow-up time has been reported except for REVERSE, making the long-term complication rate difficult to relate to other studies. The possibility of long-lasting benefit of CRT on HF progression outweighs the risk and warrants better implementation of CRT therapy than is common in today's practice of medicine. 26 
Limitations
The present results should be interpreted in light of certain limitations. First, the present cohort involved only those patients randomized to CRT ON and they were un-blinded to the pacing status following the completion of the randomization period. However, the objective endpoints evaluated in this analysis showed stable events rates during the randomized and non-randomized periods of this trial, suggesting absence of the significant effect of un-blinding. Secondly, REVERSE was a study of CRT in mild HF. Therefore, these results may not apply to subjects with more severe HF in whom the natural history and hence the possibility to affect the long-term outcome may be limited in time. Finally, this study was performed with no guidance for LV lead placement. More recent analyses of CRT trials, including REVERSE, indicate that apical pacing sites should be avoided 27, 28 and using physiological rather than anatomic markers to guide lead placement may result in improved outcomes. Whether such strategies would have affected the present outcomes is unknown.
Conclusion
The 5-year results of REVERSE confirm that CRT in mildly symptomatic HF and wide QRS reverses remodelling and modifies disease progression over time. The results support wider use of CRT in mild HF and further studies in asymptomatic (NYHA Class I) patients. 
